Osteoporosis International

, Volume 19, Issue 8, pp 1109–1117 | Cite as

Management of patients with Paget’s disease: a consensus document of the Belgian Bone Club

  • J.-P. DevogelaerEmail author
  • P. Bergmann
  • J.-J. Body
  • Y. Boutsen
  • S. Goemaere
  • J.-M. Kaufman
  • J.-Y. Reginster
  • S. Rozenberg
  • S. Boonen
Consensus Statement


Paget’s disease of bone (PDB) is a potentially crippling condition. Pain, fracture, spinal stenosis, nerve entrapment, vascular steal syndrome, secondary osteoarthritis, bone deformity, dental problems, deafness, excessive bleeding during orthopaedic surgery, rare sarcomatous degeneration, and hypercalcaemia constitute complications that may impair the quality of life. The therapeutic approach varies from symptomatic (analgesics, anti-inflammatory drugs) to more specific drugs such as increasingly potent bisphosphonates. Studies such as the PRISM study should in the future help to determine the superiority or not of aggressive treatment over symptomatic treatment in the prevention of complications. Various oral and/or intravenous (I.V.) bisphosphonates have been tested and are currently on the market. The most recently available nitrogen-containing bisphosphonate, I.V. zoledronic acid, is the most potent therapy available for the treatment of PDB. Its therapeutic efficacy, its long-term effect on biologic activity and its good tolerance currently supports its use as a first-line therapeutic option in patients suffering from PDB.


Bisphosphonates Calcitonin Paget’s disease of bone Therapy 



We thank Marie-Christine Hallot for expert technical assistance.

Conflicts of interest

J.P. Devogelaer participated in industry-supported trials on salcatonin (Sandoz, Novartis), etidronate (Procter & Gamble), tiludronate (Sanofi), risedronate (Procter & Gamble) and zoledronic acid (Novartis). Lecture fees or paid advisory board: Lilly, MSD, Novartis, Roche, Servier.

J.M. Kaufman and S. Goemaere declare themselves to have participated in company-sponsored clinical trials involving alendronate (Merck & Co), risedronate (Procter & Gamble), tiludronate (Sanofi-Synthelabo), ibandronic acid (Roche) and zoledronic acid (Novartis), and to have received speaker’s fees and research grants from Procter & Gamble, Sanofi-Aventis, Merck & Co, Roche and GlaxoSmithKline.

Jean-Yves Reginster on behalf of the Department of Public Health Epidemiology and Health Economics of the University of Liège, Liège, Belgium. Date: March 12, 2008. Consulting fees or paid advisory boards: Servier, Novartis, Negma, Lilly, Wyeth, Amgen, GlaxoSmithKline, Roche, Merckle, Nycomed, NPS, Theramex, UCB. Lecture fees when speaking at the invitation of a commercial sponsor: Merck Sharp and Dohme, Lilly, Rottapharm, IBSA, Genevrier, Novartis, Servier, Roche, GlaxoSmithKline, Teijin, Teva, Ebewee Pharma, Zodiac, Analis, Theramex, Nycomed, Novo-Nordisk. Grant Support from Industry: Bristol Myers Squibb, Merck Sharp & Dohme, Rottapharm, Teva, Lilly, Novartis, Roche, GlaxoSmithKline, Amgen, Servier.

P. Bergmann, J.J. Body, Y. Boutsen and S. Rozenberg declare that they have no conflict of interest in the field.

S. Boonen is Senior Clinical Investigator of the Fund for Scientific Research—Flanders, Belgium (F.W.O.—Vlaanderen) and holder of the Leuven University Chair in Metabolic Bone Diseases, supported by Roche & GSK. Dr. Boonen reports having received consulting fees, lecture fees and research support from Novartis, Sanofi-Aventis and Procter & Gamble Pharmaceuticals.


  1. 1.
    Paget J (1877) On a form of chronic inflammation of bones (Osteitis Deformans). Med Chir Trans Lond 60:37–63Google Scholar
  2. 2.
    Hosking D, Meunier PJ, Ringe HD, Reginster J-Y, Gennari C (1996) Fortnightly review: Paget’s disease of bone: diagnosis and management. Br Med J 312:491–494Google Scholar
  3. 3.
    Delmas PD, Meunier PJ (1997) Drug therapy: the management of Paget’s disease of bone. N Engl J Med 336:558–566PubMedCrossRefGoogle Scholar
  4. 4.
    Lyles KW, Siris ES, Singer FR, Meunier PJ (2001) Perspective. A clinical approach to diagnosis and management of Paget’s disease of bone. J Bone Miner Res 16(8):1379–1387PubMedCrossRefGoogle Scholar
  5. 5.
    Selby PL, Davie MWJ, Ralston SH, Stone MD (2002) Guidelines on the management of Paget’s disease of bone. Bone 31(3):10–19CrossRefGoogle Scholar
  6. 6.
    Scarsbrook A, Brown M, Wilson D (2004) UK guidelines on management of Paget’s disease of bone. Rheumatology 43:399–400PubMedCrossRefGoogle Scholar
  7. 7.
    Langston AL, Ralston SH (2004) Management of Paget’s disease of bone. Rheumatology 43:955–959PubMedCrossRefGoogle Scholar
  8. 8.
    Whyte MP (2006) Paget’s disease of bone. N Engl J Med 355:593–600PubMedCrossRefGoogle Scholar
  9. 9.
    US Department of Health and Human Services. Agency for Health care policy and research (1993) Acute pain management: operative or medical procedures and trauma. Clinical Practice Guidelines n°1. AHCPR Publication # 92–0023, p 107Google Scholar
  10. 10.
    Devogelaer JP, Nagant de Deuxchaisnes C (2003) Paget’s disease of bone. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds). Rheumatology, vol 2, 3rd edn. Mosby, London, pp 2139–2147Google Scholar
  11. 11.
    Barker DJ, Clough PW, Guyer PB, Gardner MJ (1977) Paget’s disease of bone in 14 British towns. Br Med J 1:1181–1183PubMedGoogle Scholar
  12. 12.
    Cooper C, Schafheutle K, Dennison E, Kellingray S, Guyer P, Barker D (1999) The epidemiology of Paget’s disease in Britain: is the prevalence decreasing ? J Bone Miner Res 14:192–197PubMedCrossRefGoogle Scholar
  13. 13.
    Cundy HR, Gamble G, Wattie D, Rutland M, Cundy T (2004) Paget’s disease of bone in New Zealand: continued decline in disease severity. Calcif Tissue Int 75:358–364PubMedCrossRefGoogle Scholar
  14. 14.
    Morales-Piga AA, Bachiller-Corral FJ, Abraira V, Beltran J, Rapado A (2002) Is clinical expressiveness of Paget’s disease of bone decreasing ? Bone 30:399–403PubMedCrossRefGoogle Scholar
  15. 15.
    Rapado A, Jimenez J, Morales A, Carbonell J, Del Pino J (1999) Patterns of diagnosis of Paget’s disease in Spain. J Bone Miner Res 14 [Suppl 2]:S96–S98Google Scholar
  16. 16.
    Tiegs RD, Lohse CM, Wollan PC, Melton LJ (2000) Long-term trends in incidence of Paget’s disease of bone. Bone 27:423–427PubMedCrossRefGoogle Scholar
  17. 17.
    Gennari L, Di Stefano M, Merlotti D et al (2005) Prevalence of Paget’s disease of bone in Italy. J Bone Miner Res 20:1845–1850PubMedCrossRefGoogle Scholar
  18. 18.
    Detheridge FM, Guyer PB, Barker DJP (1982) European distribution of Paget’s disease of bone. Br Med J 285:1005–1008Google Scholar
  19. 19.
    Lucas GJA, Daroszewskia A, Ralston SH (2006) Contribution of genetic factors to the pathogenesis of Paget’s disease of bone and related disorders. J Bone Miner Res 21 [Suppl 2]:P31–P37PubMedCrossRefGoogle Scholar
  20. 20.
    Collins DH (1956) Paget’s disease of bone. Incidence and subclinical forms. Lancet 2:51–57CrossRefGoogle Scholar
  21. 21.
    Altman RD (1980) Musculoskeletal manifestations of Paget’s disease of bone. Arthritis Rheum 23:1121–1127PubMedCrossRefGoogle Scholar
  22. 22.
    Fernandez S, Tiessen L, Powell-Tuck J, Beck S, Johansen A (2007) Pagetic hip fracture. How big is the problem? Osteoporos Int 18 [Suppl 3]:S292Google Scholar
  23. 23.
    Sundaram M (2006) Imaging of Paget’s disease and fibrous dysplasia. J Bone Miner Res 21 [Suppl 2]:P28–P30PubMedCrossRefGoogle Scholar
  24. 24.
    Maldague B, Malghem J (1987) Dynamic radiologic patterns of Paget’s disease of bone. Clin Orthop 217:126–151PubMedGoogle Scholar
  25. 25.
    Meunier PJ, Vignot E (1995) Therapeutic strategy in Paget’s disease of bone. Bone 17 [Suppl 5]:489S–491SPubMedCrossRefGoogle Scholar
  26. 26.
    Siris ES, Lyles KW, Singer FR, Meunier PJ (2006) Medical management of Paget’s disease of bone. Indications for treatment and review of current therapies. J Bone Miner Res 21 [Suppl 2]:P94–P98PubMedCrossRefGoogle Scholar
  27. 27.
    Nagant de Deuxchaisnes C, Devogelaer JP (1989) Surveillance et suivi à long terme de la maladie osseuse de Paget. In: Simon L, Sébert JL, Hérisson C (eds) La maladie osseuse de Paget: actualités. Masson, ParisGoogle Scholar
  28. 28.
    Kanis JA (1998) Pathophysiology and treatment of Paget’s disease of bone, 2nd edn. Dunitz, LondonGoogle Scholar
  29. 29.
    Van Staa TP, Selby P, Leufkens HGM, Lyles K, Sprafka JM, Cooper C (2002) Incidence and natural history of Paget’s disease of bone in England and Wales. J Bone Miner Res 17:465–471PubMedCrossRefGoogle Scholar
  30. 30.
    Gold DH, Burchett BM, Shipp KM, Pieper CF, Lyles KW (1999) Factors associated with self-rated health in patients with Paget’s disease of bone. J Bone Miner Res 14 [Suppl 2]:99–102PubMedGoogle Scholar
  31. 31.
    Ralston SH, Langston AL, Campbell MK, MacLennan G, Selby PL, Fraser WD (2006) Initial results from the PRISM study: a large randomised comparative trial of intensive versus symptomatic treatment for Paget’s disease. J Bone Miner Res 21 [Suppl 1]:LB1Google Scholar
  32. 32.
    Langston AL, Campbell MK, Fraser WD, MacLennan G, Selby P, Ralston SH for the PRISM Trial Group (2007) Clinical determinants of quality of life in Paget’s disease of bone. Calcif Tissue Int 80:1–9PubMedCrossRefGoogle Scholar
  33. 33.
    Russell RG, Smith R, Preston C, Walton RJ, Woods CG (1974) Diphosphonates in Paget’s disease. Lancet 1:894–898PubMedGoogle Scholar
  34. 34.
    Garnero P, Gineyts E, Schaffer AV, Seaman J, Delmas PD (1998) Measurement of urinary excretion of nonisomerized and b-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget’s disease. Arthritis Rheum 41:354–360PubMedCrossRefGoogle Scholar
  35. 35.
    Reid IR, Davidson JS, Wattie D et al (2004) Comparative responses of bone turnover markers to bisphosphonate therapy in Paget’s disease of bone. Bone 35:224–230PubMedCrossRefGoogle Scholar
  36. 36.
    Shankar S, Hosling DJ (2006) Biochemical assessment of Paget’s disease of bone. J Bone Miner Res 21[Suppl 2]:P22–P27PubMedCrossRefGoogle Scholar
  37. 37.
    Installe J, Nzeusseu A, Bol A, Depresseux G, Devogelaer JP, Lonneux M (2005) 18F-fluoride PET for monitoring therapeutic response in Paget’s disease of bone. J Nucl Med 46:1650–1658PubMedGoogle Scholar
  38. 38.
    Nagant de Deuxchaisnes C, Maldague B, Malghem J, Devogelaer JP, Huaux JP, Rombouts-Lindemans C (1980) The action of the main therapeutic regimes on Paget’s disease of bone, with a note on the effect of vitamin D deficiency. Arthritis Rheum 23:1215–1234CrossRefGoogle Scholar
  39. 39.
    Margiloff L, Harris SS, Lee S, Lechan R, Dawson-Hughes B (2001) Vitamin D status of an outpatient clinic population. Calcif Tissue Int 69:263–267PubMedCrossRefGoogle Scholar
  40. 40.
    Chapuy M-C, Zucchelli P, Meunier PJ (1982) La fonction parathyroïdienne dans la maladie osseuse de Paget. Rev Rhum Mal Osteoartic 49:99–102PubMedGoogle Scholar
  41. 41.
    Siris ES, Clemens TP, McMahon D, Gordon A, Jacobs TP, Canfield RE (1989) Parathyroid function in Paget’s disease of bone. J Bone Miner Res 4:75–79PubMedCrossRefGoogle Scholar
  42. 42.
    Fenton AJ, Gutteridge DH, Kent GN et al (1991) Intravenous aminobisphosphonate in Paget’s disease: clinical, biochemical, histomorphometric and radiological responses. Clin Endocrinol (Oxf) 34:197–204CrossRefGoogle Scholar
  43. 43.
    Frijlink W, Bijvoet O, Te Velde J, Heynen G (1979) Treatment of Paget’s disease with 3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet i:799–803CrossRefGoogle Scholar
  44. 44.
    Siris E (1995) Paget’s disease of bone. J Clin Endocrinol Metab 80:335–338PubMedCrossRefGoogle Scholar
  45. 45.
    Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P (2007) Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 92:1415–1423PubMedCrossRefGoogle Scholar
  46. 46.
    DeRose J, Singer FR, Avramides A et al (1974) Response of Paget’s disease to porcine and salmon calcitonins: effects of long-term treatment. Am J Med 56:858–866PubMedCrossRefGoogle Scholar
  47. 47.
    Devogelaer JP (2002) Modern therapy for Paget’s disease of bone. Focus on bisphosphonates. Treat Endocrinol 1:241–257PubMedCrossRefGoogle Scholar
  48. 48.
    Delmas P, Meunier PJ (1997) The management of Paget’s disease of bone. N Engl J Med 336:558–566PubMedCrossRefGoogle Scholar
  49. 49.
    Siris E, Canfield R, Jacobs T, Stoddart K, Spector T (1981) Clinical and biochemical effects of EHDP in Paget’s disease of bone: patterns of response to initial treatment and to long-term therapy. Metab Bone Dis Relat Res 3:301–308PubMedCrossRefGoogle Scholar
  50. 50.
    Canfield R, Rosner W, Skinner J et al (1977) Diphosphonate therapy of Paget’s disease of bone. J Clin Endocrinol Metab 44:96–106PubMedCrossRefGoogle Scholar
  51. 51.
    Khairi MRA, Altman RD, DeRosa GP, Zimmermann J, Schenk RK, Johnston CC (1977) Sodium etidronate in the treatment of Paget’s disease of bone. A study of long-term results. Ann Intern Med 87:656–663PubMedGoogle Scholar
  52. 52.
    Altman RD (1985) Long-term follow-up of therapy with intermittent etidronate disodium in Paget’s disease of bone. Am J Med 79:583–590PubMedCrossRefGoogle Scholar
  53. 53.
    Yates AJP, Percival RC, Gray RES et al (1985) Intravenous clodronate in the treatment and retreatment of Paget’s disease of bone. Lancet 1:1474–1477PubMedCrossRefGoogle Scholar
  54. 54.
    Siris ES, Chines AA, Altman RD et al (1998) Risedronate in the treatment of Paget’s disease of bone: an open label, multicenter study. J Bone Miner Res 13:1032–1038PubMedCrossRefGoogle Scholar
  55. 55.
    Reid I, Nicholson GC, Weinstein R (1996) Biochemical and radiologic improvement in Paget’s disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med 101:341–348PubMedCrossRefGoogle Scholar
  56. 56.
    Gray RES, Yates AJP, Preston CJ, Smith R, Russell RGG, Kanis JA (1987) Duration of effect of oral diphosphonate therapy in Paget’s disease of bone. Q J Med 64:755–767PubMedGoogle Scholar
  57. 57.
    Siris E, Weinstein RS, Altman R et al (1996) Comparative study of alendronate versus etidronate for the treatment of Paget’s disease of bone. J Clin Endocrinol Metab 81:961–967PubMedCrossRefGoogle Scholar
  58. 58.
    Roux C, Gennari C, Farrerons J et al (1995) Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget’s disease of bone. Arthritis Rheum 38:851–858PubMedCrossRefGoogle Scholar
  59. 59.
    Peris P, Alvarez L, Vidal S, Martinez MA, Monegal A, Guañabens N (2007) Treatment with tiludronate has a similar effect to risedronate on Paget’s disease activity assessed by bone markers and bone scintigraphy. Clin Exp Rheum 25:206–210Google Scholar
  60. 60.
    Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ, for the Paget’s risedronate/etidronate study group (1999) A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget’s disease of bone. Am J Med 106:513–520Google Scholar
  61. 61.
    Thiebaud D, Jaeger P, Jacquet AF, Burckhardt P (1989) Une perfusion unique de pamidronate (APD) dans la maladie de Paget de l’os. Schweiz Med Wochenschr 119:71–74PubMedGoogle Scholar
  62. 62.
    Adamson BB, Gallacher SJ, Byars J, Ralston SH, Boyle IT, Boyle BF (1993) Mineralisation defects with pamidronate therapy for Paget’s disease. Lancet 342:1459–1460PubMedCrossRefGoogle Scholar
  63. 63.
    Bombassei GJ, Yocono M, Raisz LG (1994) Effects of intravenous pamidronate therapy on Paget’s disease of bone. Am J Med Sci 308:226–233PubMedGoogle Scholar
  64. 64.
    Reid IR, Miller P, Lyles K et al (2005) Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N Engl J Med 353:898–908PubMedCrossRefGoogle Scholar
  65. 65.
    Markowitz GS, Fine PL, Stack JI et al (2003) Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64:281–289PubMedCrossRefGoogle Scholar
  66. 66.
    Hosking D, Lyles K, Brown J et al (2007) Long-term control of bone turnover in Paget’s disease with zoledronic acid and risedronate. J Bone Miner Res 22:142–148PubMedCrossRefGoogle Scholar
  67. 67.
    Lecompte P, Devogelaer JP, Kaufman JM, Goemaere S, Geusens P, Engbersen A (2005) Cost-effectiveness analysis of Aclasta in Paget’s disease of bone in Belgium. Value Health 8:A73Google Scholar
  68. 68.
    Kurth AA, Kotowa W, Goel D, Maiwenn JA (2006) Long-term cost-effectiveness of zoledronic acid versus risedronate in patients with Paget’s disease of the bone in Germany. Value Health 9(6):A220Google Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2008

Authors and Affiliations

  • J.-P. Devogelaer
    • 1
    Email author
  • P. Bergmann
    • 2
  • J.-J. Body
    • 3
  • Y. Boutsen
    • 4
  • S. Goemaere
    • 5
  • J.-M. Kaufman
    • 5
  • J.-Y. Reginster
    • 6
  • S. Rozenberg
    • 7
  • S. Boonen
    • 8
  1. 1.Service de Rhumatologie, Cliniques Universitaires Saint-LucUniversité catholique de LouvainBrusselsBelgium
  2. 2.Department of Nuclear Medicine, CHU BrugmannUniversité Libre de BruxellesBrusselsBelgium
  3. 3.Department of Medicine, CHU BrugmannUniversité Libre de BruxellesBrusselsBelgium
  4. 4.Department of RheumatologyMont-Godinne University Hospital, Université catholique de LouvainBrusselsBelgium
  5. 5.Unit for Osteoporosis and Metabolic Bone DiseasesGhent University HospitalGhentBelgium
  6. 6.Bone and Cartilage Metabolism UnitUniversity of LiègeLiègeBelgium
  7. 7.Department of Gynaecology-ObstetricsFree University of BrusselsBrusselsBelgium
  8. 8.Bone Research Unit, Leuven University Department of Experimental MedicineKatholieke Universiteit LeuvenLeuvenBelgium

Personalised recommendations